Macquarie Group LTD Atea Pharmaceuticals, Inc. Transaction History
Macquarie Group LTD
- $90.3 Billion
- Q3 2024
A detailed history of Macquarie Group LTD transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 70,000 shares of AVIR stock, worth $227,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,000
Previous 70,000
-0.0%
Holding current value
$227,500
Previous $231,000
1.3%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AVIR
# of Institutions
112Shares Held
52.4MCall Options Held
900Put Options Held
126K-
Black Rock Inc. New York, NY9.12MShares$29.6 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN6.65MShares$21.6 Million13.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.44MShares$17.7 Million0.79% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.85MShares$15.8 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.61MShares$15 Million1.31% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $271M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...